Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin in FET-Fusion Tumors
NCT05918640Phase 2Recruiting
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Jul 2023
- Primary completion
- Jul 2028
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of lurbinectedin in solid tumor, Ewing sarcoma, desmoplastic small round cell tumor (DSRCT), sponsored by Children's Hospital of Philadelphia. Started Jul 2023; status: recruiting.
02
Drugs
lurbinectedin
03
Conditions
solid tumorEwing sarcomadesmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on NCT05918640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05918640.